Answers are grounded in this paper and cite their sources.
BACKGROUND Patients with mild Alzheimer’s disease (AD) frequently suffer from comorbid anxiety and depression, which exacerbate neuropsychiatric symptoms, reduce quality of life, and increase caregiver burden. Conventional pharmacological treatments often inadequately address these multifaceted issues. AIM To evaluate the impact of a multicomponent, nonpharmacological care program on the neuropsychiatric symptoms, quality of life, caregiver burden, cognitive function, and sleep quality in patients with mild AD experiencing comorbid anxiety and depression. METHODS A retrospective analysis was conducted on 200 individuals diagnosed with mild AD and exhibited symptoms of anxiety and depression [Geriatric Anxiety Inventory-Short Form (GAI-SF) ≥ 3; Geriatric Depression Scale-15 (GDS-15) ≥ 6]. The patients received either conventional care (donepezil 5 mg/day plus basic health education, n = 104) or a multicomponent, nonpharmacological care program (additional 24 sessions over 12 weeks including cognitive rehabilitation, occupational therapy, art/doll therapy, exercise training, and speech therapy, n = 96). Evaluations were conducted at baseline and following a 3-month period using the Neuropsychiatric Inventory (NPI), GAI-SF, GDS-15, AD Cooperative Study Activities of Daily Living (ADCS-ADL), Quality of Life-AD (QOL-AD), Zarit Caregiver Burden Interview (ZBI), Mini-Mental State Examination (MMSE), AD Assessment Scale-Cognitive Subscale (ADAS-cog), and Pittsburgh Sleep Quality Index (PSQI). RESULTS At 3 months, the multicomponent group showed the following markedly superior outcomes than the conventional group: Lower NPI total symptom score (P = 0.004) and caregiver distress (P = 0.020); Lower GAI-SF (P = 0.003) and GDS-15 (P = 0.003); Higher ADCS-ADL (P < 0.001) and QOL-AD (P < 0.001); Lower ZBI (P = 0.004); Higher MMSE (P = 0.004) and lower ADAS-cog (P = 0.024); and lower PSQI (P < 0.001). CONCLUSION The multicomponent, nonpharmacological care program is associated with improved neuropsychiatric symptoms, anxiety, depression, quality of life, caregiver burden, cognitive function, and sleep quality in patients with mild AD experiencing anxiety and depression.
No takes yet. Share an insight, caveat, or question.
Ya-fei et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: